Your doctor can help determine whether libido changes represent a medication side effect, a consequence of rapid weight loss, an unrelated medical condition, or a combination of factors
The worlds first GLP-1 weight loss treatment is being administered for pets on an experimental basis
Allelic Polymorphism of Endothelial NO-Synthase Gene and its Functional Manifestations
Near ETSU campus, Niswonger Childrens Hospital, and Johnson City Medical Center
Used by many of our weight loss patients as a between-IV booster on a GLP-1 protocol
The FDA, EMA, and other comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need